Prof Stephen Johnston speaks on treatment of breast cancer and advanced breast cancer with aromotase inhibitors, tamoxifen, fulvestrant and previous trials using endocrine therapy at EBCC 8.

Prof Johnston highlights the need for selecting patients in these trials that will benefit from the trials as many only extend progression free survival by three to four months.